In a first for adults in Singapore, scientists are conducting gene editing trials on heart patients to correct defects at ...

Some of the most expensive drugs currently in use are gene therapies to treat specific diseases, and their high cost limits ...

The company intends to divest Roctavian and “remove it from our portfolio,” CEO Alexander Hardy said, after nearly three ...

Despite challenges like high costs and regulatory complexities, Europe's vibrant research ecosystem and EMA's supportive ATMP ...

"Eli Lilly buys Adverum in eye disease gene therapy punt" was originally created and published by Pharmaceutical Technology, ...

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing ...

4D Molecular Therapeutics has sold the Asia-Pacific rights to its eye gene therapy to Otsuka Pharmaceutical, securing $85 ...

Oncologists' experience with CGT has increased, with more patients treated and earlier lines of therapy being utilized.

A top US regulator plans to unveil a faster approach to approving custom gene-editing treatments, a move designed to unleash a wave of industry investment that will yield cures for patients with rare ...

Hyderabad- and Cambridge-based biotech startup Helex will use the capital to advance its gene therapy platform and develop ...

The trial was small — just 12 children were treated in one or both ears — but it offers important lessons for researchers about the potential of Regeneron’s gene therapy.